Gestational breast cancer: distinctive molecular and clinico-epidemiological features
Por:
de la Haba-Rodríguez J, Mínguez P, Rojo F, Martín M, Alba E, Servitja S, Prat A, Pérez-Fidalgo J, Gavilá J, Morales C, Rodriguez-Lescure A, Herrero C, Peña-Enriquez R, Herranz J, Hernando C, Hernández-Blanquisett A, Guil-Luna S, Martinez M, Blanch S, Caballero R, Martín N, Pollán M, Guerrero-Zotano A, Bermejo B
Publicada:
1 dic 2024
Ahead of Print:
8 nov 2024
Resumen:
Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse prognosis than non-GBC, but reasons behind are not clear. The GEICAM/2012-03 Study (Molecular Characterization of Gestational Breast Cancer) is a multicenter prospective/retrospective observational registry of patients diagnosed with GBC. From November 2014 to June 2015 seventy patients diagnosed with GBC were included in the study, 30 diagnosed during pregnancy and 40 after delivery. Our current study was aimed to explore differences in epidemiological, clinico-pathological and gene expression features of GBC tumors, from the GEICAM/2012-03 Study, compared to non-GBC tumors from patients of similar age (< 43 years) from six different GEICAM studies, used as non- GBC control population. As per the main objective, the study found multiple differences showing GBC tumors as a different biological entity. GBC showed a more aggressive biology, with higher Ki67 levels, higher incidence of breast and/or ovarian cancer family history, and germline deleterious BRCA1/2 mutations, and are enriched in basal-like intrinsic subtype. GBC patients showed a lower number of tumor infiltrating lymphocytes, while specific genetic signatures highlight differences in GBCs distinctive transcriptome. Our study shows that GBC is potentially a clinically and molecularly different entity, with specific epidemiological, clinical, and histological features, as well as a distinctive altered immune state and genetic signature. Nevertheless, further studies are needed to better understand the biology of GBC and to identify new targets against which develop new, more effective, targeted therapies.
Filiaciones:
de la Haba-Rodríguez J:
Univ Cordoba, Hosp Univ Reina Sofia, Med Oncol Dept, Inst Maimonides Invest Biomed Cordoba IMIBIC, Ave Menendez Pidal S-N, Cordoba 14004, Spain
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Mínguez P:
Univ Autonoma Madrid IIS FJD UAM, Fdn Jimenez Diaz Univ Hosp, Inst Invest Sanitaria, Bioinformat Unit, Madrid, Spain
Univ Autonoma Madrid IIS FJD, Fdn Jimenez Diaz Univ Hosp, Dept Genet, Inst Invest Sanitaria, Madrid, Spain
Ctr Biomed Network Res Rare Dis CIBERER, ISCIII, Madrid, Spain
Rojo F:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Hosp Univ Fdn Jimenez Diaz, Pathol Serv, Madrid, Spain
Martín M:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Med Oncol, Med Dept, Madrid, Spain
Alba E:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Hosp Univ Reg & Virgen de La Victoria, Med Oncol, Malaga, Spain
Inst Invest Biomed Malaga IBIMA, Clin & Translat Res, Malaga, Spain
Servitja S:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Hosp Mar, Med Oncol, Barcelona, Spain
Prat A:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
VHIO, Translat Genom Grp, Barcelona, Spain
Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
Pérez-Fidalgo J:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Univ Valencia, Dept Med, Inst Invest Sanitaria INCLIVA, Hosp Clin Univ Valencia, Valencia, Spain
Gavilá J:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Inst Valenciano Oncol, Med Oncol, Valencia, Spain
Morales C:
Univ Cordoba, Hosp Univ Reina Sofia, Med Oncol Dept, Inst Maimonides Invest Biomed Cordoba IMIBIC, Ave Menendez Pidal S-N, Cordoba 14004, Spain
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Rodriguez-Lescure A:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Hosp Gen Univ Elche, Med Oncol, Alicante, Spain
Herrero C:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Consorcio Hosp Prov Castellon, Med Oncol, Castellon De La Plana, Spain
Peña-Enriquez R:
Univ Cordoba, Hosp Univ Reina Sofia, Med Oncol Dept, Inst Maimonides Invest Biomed Cordoba IMIBIC, Ave Menendez Pidal S-N, Cordoba 14004, Spain
Herranz J:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Hernando C:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Univ Valencia, Dept Med, Inst Invest Sanitaria INCLIVA, Hosp Clin Univ Valencia, Valencia, Spain
Hernández-Blanquisett A:
Ctr Hosp Serena Mar, Canc Inst, Cartagena, Colombia
Guil-Luna S:
Univ Cordoba, Hosp Univ Reina Sofia, Med Oncol Dept, Inst Maimonides Invest Biomed Cordoba IMIBIC, Ave Menendez Pidal S-N, Cordoba 14004, Spain
Martinez M:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Blanch S:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Inst Valenciano Oncol, Med Oncol, Valencia, Spain
Caballero R:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Martín N:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Pollán M:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
CIBERESP, Ctr Invest Biomed Red Epidemiol & Salud Publ, Madrid, Spain
Guerrero-Zotano A:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Inst Valenciano Oncol, Med Oncol, Valencia, Spain
Bermejo B:
GEICAM Spanish Breast Canc Grp, Madrid, Spain
Oncol Biomed Res Natl Network CIBERONC ISCIII, Madrid, Spain
Univ Valencia, Dept Med, Inst Invest Sanitaria INCLIVA, Hosp Clin Univ Valencia, Valencia, Spain
Green Submitted, hybrid
|